That is exactly the section I was referring to, th

Quote:

---

Unfortunately there were delays in getting the clinical study started, I don't think the agency took this treatment modality seriously and that unfortunate they put us to the back of the line, and it was made a little worse, I think, by all the noise that our president was making about Hydroxychloroquine, at the end about a study done, a non-randomized study was very selective outcomes that most scientists regard as relatively meaningless, but the president was pushing that … inevitable that ended up putting pressure on the FDA and they issued some emergency approval for Hydroxychloroquine a drug that has known significant toxicity and down side and, partly because of that, and because of all the other companies who are vying to buy for their attention, the FDA really put Leronlimab in the back burner and, so unfortunately, we have fairly compelling though anecdotal data from the emergency IND experience without having yet enrolled a randomized clinical trial.

Read More: https://investorshangout.com/post/view?id=576...z6MHF6uYUM

---